{"nctId":"NCT01455181","briefTitle":"A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary","startDateStruct":{"date":"2011-08-19","type":"ACTUAL"},"conditions":["Hypoparathyroidism"],"count":24,"armGroups":[{"label":"NPSP558","type":"EXPERIMENTAL","interventionNames":["Drug: NPSP558"]}],"interventions":[{"name":"NPSP558","otherNames":["REPEAT"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients who meet all the following inclusion criteria can be enrolled into this study:\n\n1. Signed and dated informed consent form (ICF) before any study-related procedures are performed\n2. Previously completed 24 weeks of therapy and 4 weeks of follow-up in the REPLACE study, OR Enrolled in REPLACE and dropped out during optimization, but currently meet inclusion/exclusion criteria for REPLACE\n3. Able to perform daily SC self-injections of study medication (or have a designee perform injection) via a multidose injection pen into the thigh\n4. Willingness and ability to understand and comply with the protocol\n5. Women who are: (1) postmenopausal defined as 12 months amenorrhea with appropriate serum follicle stimulating hormone (FSH) levels (\\> 40 IU/L); (2) surgically sterilized; OR (3) of childbearing potential with a negative pregnancy test at screening and who consent to use two acceptable methods of contraception for the duration of the study, with pregnancy testing at every scheduled visit during the treatment period . Female partners (who are of childbearing potential) of male study patients must also use acceptable forms of contraception during their partner's participation\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria at baseline (Visit 1) are not eligible for enrollment in this study:\n\n1. Any condition that, in the investigator's opinion after consultation with the sponsor, would preclude the safe use of NPSP558\n2. Any disease or condition in the opinion of the investigator that has a high probability of precluding the patient from completing the study or where the patient cannot or will not appropriately comply with study requirements\n3. Pregnant or lactating woman","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data.","description":"A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percentage Changes From Baseline in Active Vitamin D Dosages at Each Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.08","spread":"31.566"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-80.38","spread":"16.688"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-96.70","spread":"7.865"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-96.18","spread":"11.521"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-97.92","spread":"10.206"}]}]}]},{"type":"SECONDARY","title":"Mean Percentage Changes From Baseline in Oral Calcium at Each Visit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"36.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.4","spread":"35.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.5","spread":"33.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-71.7","spread":"38.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-76.0","spread":"40.48"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Achieving the Primary Endpoint at Each Visit","description":"A ≥ 50% reduction from baseline in dose of oral calcium or an oral calcium dose of ≤ 500 mg and a ≥ 50% reduction from baseline in dose of oral active vitamin D (calcitriol dose of ≤ 0.25 μg/day or alphacalcidol dose of ≤ 0.50 μg/day) and a total serum calcium concentration that was normalized or maintained compared to the baseline value and did not exceed the ULN of the central laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in 24-hour Urine Calcium Excretion","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.58","spread":"188.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.53","spread":"183.41"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Hypoaesthesia","Muscle spasms","Vitamin D decreased","Hypercalcaemia","Headache"]}}}